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In preclinical studies, selenite had single agent activity and radiosensitized tumors in vivo. Here we report results
from a Phase 1 trial in 15 patients with metastatic cancer treated with selenite (5.5 to 49.5 mg) orally as a single
dose 2 hours before each radiation therapy (RT) treatment. Patients received RT regimens that were standard of
care. The primary objective of the study was to assess the safety of this combination therapy. Secondary
objectives included measurement of pharmacokinetics (PK) and evaluation of efficacy. Endpoints included
assessment of PK, toxicity, tumor response, and pain before and after treatment. The half-life of selenite was 18.5
hours. There were no adverse events attributable to selenite until the 33 mg dose level, at which the primary
toxicities were grade 1 GI side effects. One patient treated with 49.5 mg had grade 2 GI toxicity. Although this
was not a DLT, it was felt that the highest acceptable dose in this patient population was 33 mg. Most patients
had stabilization of disease within the RT fields, with some demonstrating objective evidence of tumor
regression. Most patients had a marked improvement in pain and seven out of nine patients with prostate cancer
had a decrease in PSA ranging from 11e78%. Doses up to 33 mg selenite were well tolerated in combination
with RT. A randomized, well controlled study is needed at the 33 mg dose level to determine if selenite results in
clinically meaningful improvements in the response to palliative RT.
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Patients with metastatic cancer frequently receive palliative radiation
therapy to treat painful and symptomatic sites of disease. Despite
recent advances in both systemic and local treatment of metastases,
many patients have persistent pain or symptoms following treatment.
New and improved therapies are needed to increase the efficacy and
duration of response to palliative radiation therapy.
Although a large body of data exists from studies of the potential
utility of selenium supplementation (using an organic form of
selenium) as a chemopreventive strategy, little is known regarding the
use of selenium, as inorganic sodium selenite, as a cancer therapy. Our
results [1e5], as well as those of other groups [6], support the novel
idea that selenium in the form of selenite can be used to treat prostate
as well as other types of cancer. Importantly, selenite is metabolizeddifferently from organic forms of selenium, with the key difference
being that the metabolism of selenite depletes cells of an important
antioxidant, glutathione (GSH), and results in the generation of
superoxide, a highly reactive and toxic radical that results in the
generation of reactive oxygen species (ROS).
Table 1. Patient characteristics
Patient no. Dose cohort (mg) Tumor
histology
Race Sex Age (y) BSA(m2) Prior therapy
1 5.5 Prostate White M 92 1.8 N/A
2 Prostate African
American
M 76 2.2 RT
3 Prostate White M 79 2 RT and ADT
4 11 Prostate White M 75 2.3 ADT
5 Prostate African
American
M 71 - N/A
6 Prostate White M 82 1.9 N/A
7 16.5 Prostate White M 68 - N/A
8 Prostate White M 68 1.7 RT
9 Prostate White M 65 1.7 RT and ADT
10 33 Prostate White M 91 1.8 N/A
11 Multiple
myeloma
White M 57 2.4 RT, RVD, and
CT
12 MPNST Asian M 37 1.8 RT and CT
13 NSCLC White M 67 1.9 RT and CT
14 Multiple
myeloma
White F 37 1.6 RVD
15 49.5 NSCLC African
American
F 56 1.7 RT and CT
Abbreviations: ADT¼ androgen deprivation therapy, BSA¼ body surface area calculated with Du
Bois formula, CT¼ chemotherapy, MPNST¼malignant peripheral nerve sheath tumor,
NSCLC¼ non-small cell lung cancer, RT¼ radiation therapy, RVD¼ lenalidomide, bortezomib,
and dexamethasone.
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using selenite to treat prostate cancer came from our preclinical
studies showing that 1) prostate cancer cells are more sensitive to
selenium (sodium selenite)-induced apoptosis than normal prostate
epithelial cells, 2) Selenite induces significant growth inhibition of
well-established prostate cancer tumors in mice at doses that have no
detectable toxicity when administered both ip and po, and 3) Selenite
disrupts androgen receptor (AR) signaling, with inhibition of AR
expression and activity by selenite occurring via a redox mechanism
involving GSH, superoxide, and transcription factor Sp1. Altogether,
these findings suggest that selenite may be useful in a variety of
potential indications in the natural history of prostate cancer,
including both hormone sensitive and hormone refractory prostate
cancer, as a single agent, or in combination with radiation,
chemotherapy or conventional androgen deprivation therapy (ADT).
Given that depletion of GSH is known to have radiosensitizing
effects [7], and generation of superoxide should enhance the efficacy
of radiation-induced ROS, selenite has the potential to sensitize a
wide range of tumor types. Our data suggests that selenite-mediated
tumor-selective radiosensitization in prostate cancer is due, in part, to
differences between MnSOD and Bcl-2 family member expression in
tumor vs. normal tissue [3]. Similar differences in other tumor types,
as well as overexpression of Nrf2 and its downstream target genes in
cancer [8], may also contribute to the differential sensitizing effects of
selenite.
In the Phase 1 trial described here, sodium selenite (given orally at
daily doses of 5.5, 11, 16.5, 33 and 49.5 mg) was given concurrently
with palliative radiation therapy in patients with metastatic cancer.
The primary objective of the study was to assess the safety and
tolerability of this combination therapy. Secondary objectives
included measurement of pharmacokinetics and evaluation of
efficacy. The underlying hypothesis of this study was that the
combination of selenite and radiation therapy would be safe and
tolerable, and might have the potential to improve PSA responses in
the subset of patients with castration-resistant prostate cancer
(CRPC) and local response to radiation therapy in patients with
metastatic cancer.
Methods
Patients
This study was approved by the Food and Drug Administration
(IND 122151), the Stanford University Internal Review Board, and
the Scientific Review Committee for the Stanford Cancer Institute.
Fifteen patients with a variety of malignancies were treated on this
study. The study was initially open only to prostate cancer patients,
but then expanded to include a variety of tumor types. Patient
characteristics are summarized in Table 1, including tumor histology,
race, sex, age, BSA and history of prior therapy. Patients ranged in age
from 37 to 92 years of age, with 13 men and two women. Before
study entry, patients had to meet a number of eligibility criteria.
Inclusion criteria included a) histologically-confirmed solid tumor
malignancy with confirmation of metastasis, multiple myeloma, or
plasmacytoma, b) need for palliative radiation therapy, c) for prostate
cancer patients, PSA at least 2 ng/mL, except for patients who had
recently started androgen deprivation therapy with PSA less than 2
ng/mL, d) age 18 years, e) life expectancy greater than 3 months, f)
Eastern Cooperative Oncology Group (ECOG) performance status of
zero or one or Karnofsky performance status 80%, and g) QTinterval corrected using Fridericia's method (QTcF) <460 msec.
Exclusion criteria included a) Absolute neutrophil count <1500/mL,
platelet count 100  109/L, serum creatinine >2.0 mg/dL, total
bilirubin >1.5  upper limit of normal (ULN), AST, and/or ALT
>2  ULN, hemoglobin <9 g/dL, b) history of other malignancies
within 5 years prior to Day 1 except for tumors that in the opinion of
the investigators have a negligible risk for metastasis or death, such as
adequately controlled basal cell carcinoma, squamous-cell carcinoma
of the skin, or early-stage bladder cancer, c) current, or recent (within
4 weeks of the first treatment of this study) cytotoxic chemotherapy
(eg, cisplatin, Taxol) or experimental drug therapy, d) uncontrolled
inter-current illness, or psychiatric illness/social situations that would
limit compliance with study requirements, e) history of myocardial
infarction or unstable angina within 6 months prior to study
enrollment, f) history of stroke or transient ischemic attack within 6
months prior to study enrollment, g) known human immunodefi-
ciency virus (HIV) positivity while receiving antiretroviral therapies,
and i) pregnant or breastfeeding women.Study Design
This was a Phase 1 study, with the “3 þ 3” rule used for dose
escalation of sodium selenite. Patients were treated in groups of three
with each receiving the same dose. Sodium selenite (Biosyn,
Germany) was given orally 2 hours prior to scheduled daily radiation
therapy treatments for the duration of the radiation therapy course.
The initial dose escalation schema was 5.5, 11, 16.5, 33, 49.5, 66, 99,
and 121 mg daily. Dose escalation was to proceed as follows: a) if
none of the three patients experienced a dose limiting toxicity (DLT),
dose escalation to the next dose level would occur, b) if one of three
patients treated at that dose level experienced a DLT, that dose level
would be expanded to six subjects; if no additional patient in that
cohort experienced a DLT, dose escalation to the next dose level
would occur, c) if two patients in a cohort experienced a DLT, dose
escalation would stop and the prior dose would be considered the
Table 3. Adverse events
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expanded to a total of six patients.
Baseline evaluations included EKG, PSA for prostate cancer
patients, CBC with differential, CMP, LDH, bone scan (BS), or CT,
PET/CT or MRI as clinically indicated to monitor response to
therapy. Palliative radiation therapy utilized standard of care palliative
dose/fractionation regimens. A summary of radiation therapy
parameters and concurrent therapy are summarized in Table 2. On
Week 1, Day 1 patients underwent physical exam (PE), laboratory
studies as above and EKG. All patients completed a pain inventory,
the Brief Pain Inventory [9,10], prior to therapy. Sodium selenite was
begun 2 hours prior to the scheduled radiation therapy appointment
time. Weekly, during radiation therapy, patients had vital signs
performed, with assessment of adverse events (AEs), labs and EKG if
clinically indicated. The pain inventory was completed again on the
last day of radiation therapy. Following completion of therapy, the
first follow-up visit was within 2e3 months þ/ 2 weeks, with
subsequent follow-up visits optional until progression of disease at the
site of radiation. At these visits patients had a PE, labs and imaging.
They also completed another pain inventory.Cohort-
selenite
dose
(mg)
Classification Type Grade
attribution
Number of
occurrences
Number
of
subjects
affected
Relation to
selenite
33 Blood and
lymphatic
system
Anemia 3 1 1 Unrelated
Gastrointestinal Abdominal
pain
1 3 3 1 - P o s s i b l e ,
2-Probably
Diarrhea 1 5 4 2 - P o s s i b l e ,
3-Probable
Dysphagia 1 1 1 Unrelated
Nausea 1 8 5 7 -P r ob ab l e ,
1-Unrelated
Nausea 2 1 1 P r o b a b l e /
Definite
Vomiting 1 6 2 4 -P r ob ab l e ,
2-Unlikely
Vomiting 2 1 1 ProbablePharmacokinetic Analysis
Pharmacokinetic Studies. Pharmacokinetic blood sampling was
performed on Day 1 pre-dose, 15 minutesþ/ 2 minutes, 1 hourþ/
 5 minutes, 2 hoursþ/ 10 minutes, 4 hoursþ/ 15 minutes, and
24 hours þ/ 1 hour. During week 2, on Day 1 pre-dose, 1 hour þ/
 5 minutes, and other optional time points were obtained when
feasible.
Pharmacokinetic analysis and model simulations. The PK profile
of selenite was characterized using nonlinear mixed effects (NLME)
modeling. Using NONMEM software (version 7.4; ICON PLC,
Dublin, Ireland), a 1-compartment model with oral absorption was fit
to the data. PK parameter estimates obtained from the model
included bioavailability (F), clearance (CL/F), and volume ofTable 2. Radiation treatment parameters
Patient
no.
Radiation field(s) Dose/Fx y
(cGy)
N umb e r
of Fx y
Total dose
(cGy)
Concurrent therapy
1 Bilateral pelvic bones 800 1 800 Abiraterone
2 Left shoulder and left hip 400 5 2000 B i c a l u t a m i d e ,
leuprolide acetate
3 Bilateral sacroiliac joints 400 5 2000 A b i r a t e r o n e ,
leuprolide acetate
4 Bilateral sacroiliac joints 400 5 2000 B i c a l u t a m i d e ,
leuprolide acetate
5 Left pelvis and proximal
femur
300 10 3000 Leuprolide acetate
6 T3-T6 400 5 2000 N/A
7 C7-T4 & right humerus 400 5 2000 N/A
8 L2 800 3 2400 Enzalutamide
9 T11 2000 1 2000 B i c a l u t a m i d e ,
leuprolide acetate
10 L1-L4 400 5 2000 E n z a l u t a m i d e ,
leuprolide acetate
11 Left arm, left and right
femur, left leg
300 10 3000 N/A
12 Right lung 500 10 5000 Olaratumab
13 Left hip 300 10 3000 Pembrolizumab
14 Right sacroiliac and
sternum
400 5 2000 N/A
15 Sacrum and skull/dura 400 5 2000 N/A
y Fx¼ Fraction.distribution (V/F). These estimates were used to determine the
half-life (t1/2) using the relationship t1/2¼ 0.693/kelimination
(kelimination¼CL/V) and area under the curve (AUC) using the
relationship AUC¼ (F*dose)/CL. A full description of the structural
and statistical model development will be the subject of a separate
paper.
Using the final model and its parameter estimates, a simulation was
performed for each dose level (5.5 mg, 11 mg, 16.5 mg, 33 mg, 49.5
mg) assuming a single dose administration. Additionally, using the
dose levels 11 mg, 16.5 mg and 33 mg, a dosing regimen (dose,
frequency) was proposed to achieve a target selenite concentration of
5e10 mM (395e790 mcg/L). This therapeutic range was determined
by concentrations of selenite/selenium that had activity in vitro, as
well as PK studies in mice given 2 mg/kg sodium selenite iv, which
was a dose that had significant activity in vivo (unpublished data).
The PKPDsim package in R was used to perform simulations.General Facial pain 1 1 1 Unrelated
Fatigue 1 2 2 Possible
2 2 1 U n r e l a t e d ,
Possible
Flu-like
symptoms
1 2 1 Unrelated
Infection and
Infestation
Upper
respiratory
infection
1 1 1 Unrelated
Injury F a l l
(Mechanical)
2 2 1 Unrelated
Investigations ECG QTcF
prolonged
1 2 2 Probable
Musculoskeletal
and Connective
Tissue
Bone pain 1 1 1 Unrelated
Back pain 1 1 1 Unrelated
Nervous System Dizziness 1 1 1 Probable
Paresthesia 1 1 1 Unrelated
Respiratory,
Thoracic and
Mediastinal
Dyspnea 1 1 1 Unrelated
Dyspnea 2 1 1 Unrelated
Sore throat 1 1 1 Unrelated
49.5 Gastrointestinal Diarrhea 2 1 1 Possible
Nausea 1 1 1 Probable
2 1 1 Probable
Vomiting 1 1 1 Probable
2 1 1 Probable
General Fatigue 1 1 1 Possible
Musculoskeletal
and Connective
Tissue
Back pain 2 1 1 Unrelated
Pain in
extremity
2 1 1 Unrelated
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Toxicity Profile
Adverse events are summarized in Table 3 by dose level, in terms of
classification, type, grade, number of subjects affected and relation-
ship to selenite. At the 5.5, 11 and 16.5 mg dose levels, there were no
AEs attributable to the selenite (data not shown). At the 33 mg dose
level the majority of patients had a variety of grade 1 GI toxicities that
ranged in attribution from possibly to probable/definitely related.
This was the first dose level at which ondansetron and loperami-
de-Hcl were prescribed prn, and were highly effective in most of the
patients. One patient, with a reported low threshold for nausea, had
grade 2 nausea and vomiting that was not well controlled with
ondansetron and stopped selenite after 4 of 10 planned treatments,
with complete resolution of symptoms within 48 hours. Non-GI side
effects included one patient with grade 1 fatigue, one patient with
grade 1 dizziness, and one patient had grade 2 fatigue, that were
possibly related to the selenite treatment. In addition, two patients
had grade 1 ECG QTcF prolongations, initially scored as probably
related to the selenite. One patient was taken off the study after the
first dose of selenite when this occurred given his age of 91 years and
relatively frail condition. Pre and post selenite treatment ECGs were
subsequently reviewed by Dr. Philip Sager (Department of Medicine,
Stanford University; Executive Committee, Cardiac Safety Research
Consortium; personal communication). The observed grade 1 ECG
changes were determined to be within the range of expected
intra-subject variability, but it was not possible to exclude a potential
QTc effect of the selenite. The one patient treated at the 49.5 mg dose
level had grade 2 diarrhea, nausea and vomiting that was probably
related to selenite, as well as grade 1 fatigue that was possibly related
to the treatment. This patient required ondansetron every 8 hours as
well as loperamide-Hcl, which improved the symptomatology, but
did not completely control it. At that point, although this level of
toxicity did not meet the strict definition of a DLT, it was felt that this
toxicity profile in this patient population was not acceptable, and the
highest dose level that was reasonably well tolerated with ondansetron
prn was 33 mg.
Pharmacokinetics
Pharmacokinetic analysis and model simulations. Using the
parameter estimates from the population PK model, the half-life
was calculated to be approximately 18.5 hours. Table 4 provides the
area under the curve, the maximum concentration (Cmax), and the
time to maximum concentration (tmax) for each dose level. Figure 1A
provides a simulation using the final parameter estimates from the PK
model for each dose level after a single dose administration, which is
in alignment with the data that were collected from the study and
modeled. This simulation reveals that only the higher dose levels (33
mg and 49.5 mg) reach the desired therapeutic range after a singleTable 4. PK parameters; parameters derived from the final population PK model per dose level
Dose
(mcg)
AUC
(mcg  hour/L)
Cmax
(mcg/L)
tmax
(hour)
5500 3629 214.9 3.65
1100 6160 300.8 4.05
16,500 8277 365.6 4.15
33,000 13,259 495.5 4.35
49,500 16,997 593.0 4.40dose. Figure 1B provides a simulation for a new proposed dosing
regimen of 11 mg dosed twice daily to achieve and remain within the
desired concentration range.
Clinical Responses
It is important to note that patient numbers were small, and the
patient population heterogeneous, so it is not possible to draw any
definitive conclusions about efficacy. Nevertheless, data were
gathered for PSA in the subset of patients with prostate cancer
(Table 5). All patients completed a pain inventory prior to treatment,
on the last day of radiation therapy and at their first follow up visit
(Table 6). Tumor response in the irradiated field was assessed as well
(Table 7). An example of the response observed in a patient with
CRPC is shown in Fig. 2. A comparison of pre and post treatment
bone scans demonstrates a near complete response in the irradiated
left hip in Patient 2.
Table 5 shows PSA values on Day 1 prior to the initiation of
selenite and radiation therapy and the PSA value at the time of the
first follow up, which ranged from 2e4 months following the
completion of radiation therapy. Seven out of nine patients had a
decrease in PSA with the magnitude of change ranging from an 11%
to a 77.9% decrease. There was no evidence of a selenite dose
response relationship, but patient numbers were too small and the
patients too heterogeneous to draw a definitive conclusion about the
presence or absence of a dose response relationship. These results are
confounded by the concurrent use of ADT in the majority of the
patients with CRPC. Of note, patients were maintained on whatever
ADT they were on before study entry, as discontinuation of ADT
could have been even more of a confounding variable. Interestingly,
two of the three patients that were not receiving ADT had an increase
in PSA.
The pain inventory captured four categories of pain as follows:
worst pain in last 24 hours, least pain in last 24 hours, average pain
and pain right now. Pain was scored using a 10 point scale, on which
0 was no pain and 10 was severe pain. Table 6 shows the average
change in numerical value compared to baseline for two time points,
baseline compared to the last day of radiation therapy, and baseline
compared to the first follow up visit as a function of dose level. A
change of at least one point was felt to be clinically meaningful. As can
be seen, there was a generalized improvement in pain in all four
categories at both time points, with a suggestion of a dose response
relationship with some increase in pain (decreased change from
baseline) in the lowest dose groups of 5.5 and 11 mg, but sustained or
improved pain in the higher dose groups. These results are potentially
confounded by a variety of factors including extent of disease,
systemic therapy and pain medicine usage.
Lastly, tumor responses in the irradiated field are summarized in
Table 7. All but one patient received palliative radiation therapy to
symptomatic bone metastases. Quantitation of response in bone is
difficult and imprecise. Furthermore, patients were imaged as per
standard of care, using a variety of imaging modalities, including bone
scan, which is not applicable to RECIST scoring. Acknowledging
these limitations, of the evaluable patients (n¼ 13), eight patients
had stable disease (SD) within the irradiated field (includes patient 10
with two sites of disease irradiated, with site dependent SD and
progressive disease (PD) in the two sites respectively. Another patient
also had PD. The remaining patients had significant improvement
with complete resolution of bone scan abnormalities in two irradiated
fields (patients two and four). Patient two also had a greater than 50%
Fig. 1.Dosing simulations. (a) Single dose simulation and (b) proposed dose simulation using the final population PKmodel; desired
systemic sodium selenite range demarcated by 395 and 790 mcg/L (lower and upper black dotted lines, respectively).
Table 6. Average pain reduction
Average change in numerical value from baseline
D o s e
cohort
(mg)
Total
(N¼ 15)
Assessment
timepoint
Worst pain
last 24 h
mean± SD
Least pain
last 24 h
mean ± SD
Average
pain
mean± SD
Pain right
now
mean± SD
5.5 mg 3 End of RT 4 ±
1.4
1.5 ±
2.1
2.5 ±
0.7
2 ± 0
First
follow-up
2.5 ±
0.7
1.5 ±
1.4
1.5 ±
0.7
2 ± 0
11 mg 3 End of RT 1.7 ± 2.7 ± 2.3 ± 1.7 ±
Translational Oncology Vol. 12, No. 11, 2019 Phase 1 Study of Selenite in Combination with Radiation Therapy Knox et al. 1529decrease in the number and size of lesions on bone scan, and patient
11 had almost complete metabolic resolution on PET CT. There was
no apparent dose response relationship.
Discussion
Given the promising results with inorganic sodium selenite in
preclinical tumor models and some early clinical trials, there is
increasing interest in using selenite as a cytotoxic agent, and/or as a
sensitizer. For example, in a study of newly diagnosed patients with
non-Hodgkin's lymphoma treated with standard chemotherapy with
or without adjuvant sodium selenite (0.2 mg/kg per day for 30 days),
the patients receiving selenite had down-regulated levels of Bcl-2 and
improved clinical outcomes [11]. In another study of selenite
(0.2 mg/kg per day for 7 days) in combination with chemotherapy,
addition of selenite resulted in a significant increase in the percentage
of apoptotic lymphoma cells and clinical response compared to
patients treated with chemotherapy alone [12]. Sodium selenite has
also been studied in a variety of other tumor types, including colon
cancer [13], and head and neck cancer [14]. In addition, patients with
multiple tumor types were enrolled in a Phase one trial: the SECAR
study, in which 34 patients with different resistant tumor typesTable 5. PSA data
Cohort-selenite
dose (mg)
P a t i e n t
number
PSA value Day
1 (ng/ml)
PSA value FU
(ng/ml)
Time to FU
visit (M)
%
Change
Change
5.5 2 39.83 8.79 2 77.9 Y
3 225 239 2.25 6.2 [
11 4 131.83 35.77 3.25 72.9 Y
5 40.61 19.25 4 52.6 Y
6 0.98 0.32 4 67.3 Y
16.5 7 1.74 21.85 2.25 1155.7 [[
8 3.3 1.34 2.75 59.4 Y
9 1 0.89 3.25 11 Y
33 10 196 64.46 3 67.1 Yreceived i.v. sodium selenite daily for 5 consecutive days either for 2 or
4 weeks [15]. The MTD was defined as 10.2 mg/m2 with a calculated
median plasma half-life of 18.25 hours. The most common side
effects were fatigue, nausea and cramps in fingers and legs [15].
While there have been no clinical trials to date studying sodium
selenite as a potential radiosensitizer, a randomized Phase three trial
studied the ability of selenium to function as a radioprotector of
normal tissues presumed to be secondary to enhanced antioxidant
capacity, as organic selenium is used for the synthesis of antioxidant
enzymes. This trial compared selenium supplementation (500 mg po1.5 3.8 4.0 2.9
First
follow-up
0.7 ±
5.0
1.3 ±
4.9
0.7 ±
4.6
1.7 ±
1.2
16.5 mg 3 End of RT 1 ±
1.4
1 ±
2.8
1.5 ±
3.5
0.5 ±
2.1
First
follow-up
0.7 ±
0.6
2.3 ±
2.1
2 ± 2 2.7 ±
3.8
33 mg 5 End of RT 1 ± 2 0.2 ±
0.5
1.2 ±
1.3
0.6 ±
1.1
First
follow-up
2 ± 2 0 ± 1 1 ± 1 0.8 ±
1.3
49.5 mg 1 End of RT 6 ± 0 5 ± 0 4.5 ± 0 4 ± 0
First
follow-up
10 ± 0 9 ± 0 8.5 ± 0 8 ± 0
Abbreviation: RT¼ radiation therapy.
Table 7. Tumor response in irradiated field
Patient
no.
Tumor response Field I m a g i n g m o d a l i t y
(months after treatment)
1 NE Bone BS (N/A)
2 Field 1: CR, Field 2: PR Bone BS (2 mo)
3 SD Bone BS (1 mo)
4 CR Bone BS (1 mo)
5 SD (Y Intensity of uptake) Bone BS (3 mo)
6 PR (change from diffuse to patch involvement with
Y intensity of uptake)
Bone BS (5 mo)
7 SD (Y intensity of uptake) Bone BS (1 mo)
8 SD Bone MRI (2 mo)
9 SD Bone CT and MRI (3 mo)
10 Field 1: PD, Field 2: SD Bone CT (4 mo)
11 PR (almost complete metabolic resolution) Bone PET-CT (6 mo)
12 SD Lymph
node
CT (1 mo)
13 PD Bone CT, MRI and PET-CT (1
mo)
14 NE (no FU scan because of clinical progression) Bone PET-CT (N/A)
15 SD Bone BS (2 mo)
NE ¼ not evaluated; no follow-up imaging.
For CT or MRI imaging: PR 30% Y sum of diameters.
PD 20% [ sum of diameters
For bone scan: CR resolution of uptake.
PR decrease in extent of involvement (# and size of lesion 50% observed).
SD same extent of involvement (# and size of lesions).
1530 Phase 1 Study of Selenite in Combination with Radiation Therapy Knox et al. Translational Oncology Vol. 12, No. 11, 2019on days of radiation therapy and 300 mg on days without radiation)
with observation in patients with gynecologic malignancies treated
with radiation therapy [16]. Interestingly, there was a reduction in the
number of episodes and severity of radiation-induced diarrhea.
More relevant to our study, is the study by Corcoran et al. [17],
using the inorganic form of selenium, sodium selenate (SeO4-, which
is not as reactive with thiols as selenite, SeO32-). In this study,Fig. 2. Patient #2, a 76-year-old male with disseminated prostate
radiotherapy for metastases in the left shoulder and left hip. Tc-9
demonstrate near complete response in the left hip (open arrowspatients with castration-resistant prostate cancer received escalating
doses of selenate orally. The MTD was 60 mg daily. Dose limiting
toxicity (fatigue and diarrhea) occurred at 90 mg daily, with no grade
4 toxicity. One patient treated with 60 mg/day had a PSA response
greater than 50% for 11 weeks, and the mean PSA doubling time
nearly doubled in patients following treatment.
Given that sodium selenite depletes GSH and generates superoxide
radicals when metabolized, it has the potential to radiosensitize
multiple tumor types. Since in our preclinical studies, it radio-
sensitized tumors in vivo and did not sensitize GI epithelium to
radiation (in fact it had a slight protective effect), it has the theoretical
potential to significantly increase the therapeutic window for
radiation therapy. This and other preclinical data to date, as well as
early clinical data for other indications, provided a compelling
rationale for the study of sodium selenite in combination with
radiation therapy. In the study described here, the safety, tolerability
and PK of sodium selenite was studied in 15 patients with advanced/
metastatic tumors receiving concurrent sodium selenite with palliative
radiation therapy. The 33 mg dose level had acceptable tolerability,
with the primary toxicity being grade 1 GI side effects. These side
effects were well controlled with ondansetron and loperamide-Hcl
prn. It was concluded that 33 mg would be a reasonable dose for
future studies when given orally, one time per day, with no oral intake
for at least 2 hours prior.
The half-life obtained from the parameter estimates of the PK
model is in agreement with what is reported in the literature. The
SECAR study reported a median half-life of approximately 18 hours
in patients with malignant disease receiving IV sodium selenite as a
single agent [15]. Corcoran et al. noted significant accumulation of
selenite, the active metabolite of selenate, following selenatecarcinoma who received sodium selenite in combination with
9 m MDP bone scans pre (A) and 15 months post (B) treatment
) and partial response in the left shoulder (arrows).
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prostate cancer [17]. The PK model we have developed for this study
captures the accumulation of selenite and appropriately characterizes
the sparse data and variability in the patient population.
From the simulations for the PK model, it takes approximately 1
day to enter the desired therapeutic range for the 11 mg dose level
when given twice daily. While a few dosing regimens are possible, 11
mg was chosen to minimize nausea.
Efforts were made to assess potential efficacy signals. Given the
inherent limitations of small numbers, and the heterogeneous patient
population in terms of tumor type, site of irradiation, radiation dose/
fractionation, prior and concurrent systemic therapies, and lack of
randomization, it is not possible to draw any definitive conclusions.
Nevertheless, the majority of patients with prostate cancer did exhibit
a decrease in PSA following treatment, and the majority of patients on
the study had a decrease in pain indices. Lastly, the majority of
patients had stabilization of disease within the radiation therapy
field(s), with some demonstrating objective evidence of tumor
regression. Similar findings can be observed in patients treated with
radiation therapy without selenite, and a randomized, well controlled,
study will be needed at the 33 mg dose level to determine if selenite
results in clinically meaningful improvements in the response to
palliative radiation therapy.
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